Race Oncology (ASX:RAC) says it has received binding commitments to raise $5.4 million before costs in an oversubscribed equity placement to new and existing institutional and sophisticated investors.

Neurotech International (ASX:NTI) has announced the commencement of a phase 1/2 open-label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder.

A drug candidate discovered by the Australian company Pharmaxis (ASX:PXS) will be the focus of a new trial aimed at studying its potential as a treatment for an aggressive and deadly form of brain cancer.

AusBiotech is inviting expressions of interest from its corporate members for its new virtual pitching series, BiotechPitch. Its new platform will profile Australian companies to investors internationally and will feature expert industry speakers and commentators offering capital insights and market updates.

Australian clinical dermatology and antimicrobial company Botanix Pharmaceuticals (ASX:BOT) has released a clinical development update of its antimicrobial platform with the identification of a potential new indication.

Recce Pharmaceuticals (ASX:RCE) has announced that its RECCE 327 has demonstrated bactericidal activity against all six antibiotic-resistant ESKAPE pathogens, including drug-resistant mutations as well as two additional WHO priority pathogens list.

Medibio (ASX:MEB) says it has been awarded a patent from the US Patent and Trademark Office for its 'Method and System for Assessing Mental State'.

CSL has announced $2 million in total funding over two years for four Australian projects under its Research Acceleration Initiative partnership.

Australia’s dynamic medtech sector is taking centre stage in the May edition of Australasian Biotechnology, AusBiotech’s official journal, in anticipation of the upcoming AusMedtech 2021 conference.

The collaborative research aims to create a new generation of microbial therapies that can replace donor-derived faecal microbiota transplantation.

Private medical technology companies Epiminder and Seer Medical have announced a collaboration to accelerate ultra-long term EEG monitoring so those people who suffer seizures may have an advanced digital therapeutics product to detect and forecast their seizures.

Regenerative medicine company Orthocell (ASX:OCC) has announced what it describes as positive results from the US animal pilot study of its CelGro in nerve regeneration compared to the current market-leading device.

A report commissioned by Bristol Myers Squibb says the federal government could use its research funding bodies to take further action on harmonising clinical trial approvals in Australia. 

The impact of the Victorian Government’s investment in health and medical research has been revealed through its newly released report ‘Creating a healthy future.’

Telix Pharmaceuticals (ASX:TLX) has announced an agreement with Global Medical Solutions to manufacture and supply finished unit doses of MTR products for clinical development programs.

Botanix Pharmaceuticals (ASX:BOT) says research on the antimicrobial potential of CBD has been supported by the publication of research data from a leading South American academic group in the online journal BioRxiv.